Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient
Open Access
- 12 October 2021
- journal article
- case report
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18 (1) , 1-4
Abstract
Background: The current standard of care is to start antiretroviral therapy in all patients diagnosed with HIV-1, as for HIV-2 current DHHS guideline suggests ART for HIV-2 as soon as diagnosis is established, although this practice is not universal, for instance, in Portugal there are specific criteria to start treatment. Case presentation: We present a case of a man, chronically infected with HIV-1, HIV-2 and hepatitis B virus who developed resistance to HIV-2 while maintaining HIV-1 under control. 6 years after starting antiretroviral therapy he had his first virologic failure. We performed HIV-2 resistance tests that revealed high-grade resistance to all nucleoside reverse-transcriptase inhibitors except tenofovir and to all protease inhibitors except darunavir. After a decade of permanent poor adherence to therapy he developed resistance to both tenofovir and darunavir. We put together a new regiment with tenofovir alafenamide + emtricitabine + dolutegravir + maraviroc and nowadays he is with undetectable HIV-1 and HIV-2 viral loads. Conclusions: This shows the importance of having access to HIV-2 viral load determination and HIV-2 resistance testing.Keywords
This publication has 6 references indexed in Scilit:
- Human Immunodeficiency Virus–2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western EuropeClinical Infectious Diseases, 2020
- Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 InfectionNew England Journal of Medicine, 2012
- Update on Human Immunodeficiency Virus (HIV)-2 InfectionClinical Infectious Diseases, 2011
- Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialAIDS, 2009
- Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patientsAIDS, 2009
- Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2006